JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors

RUNX1-RUNX1T1 (formerly AML1-ETO), a transcription factor generated by the t(8;21) translocation in acute myeloid leukemia (AML), dictates a leukemic program by increasing self-renewal and inhibiting differentiation. Here we demonstrate that the histone demethylase JMJD1C functions as a coactivator...

Full description

Saved in:
Bibliographic Details
Published in:Genes & development Vol. 29; no. 20; pp. 2123 - 2139
Main Authors: Chen, Mo, Zhu, Nan, Liu, Xiaochuan, Laurent, Benoit, Tang, Zhanyun, Eng, Rowena, Shi, Yang, Armstrong, Scott A, Roeder, Robert G
Format: Journal Article
Language:English
Published: United States Cold Spring Harbor Laboratory Press 15-10-2015
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RUNX1-RUNX1T1 (formerly AML1-ETO), a transcription factor generated by the t(8;21) translocation in acute myeloid leukemia (AML), dictates a leukemic program by increasing self-renewal and inhibiting differentiation. Here we demonstrate that the histone demethylase JMJD1C functions as a coactivator for RUNX1-RUNX1T1 and is required for its transcriptional program. JMJD1C is directly recruited by RUNX1-RUNX1T1 to its target genes and regulates their expression by maintaining low H3K9 dimethyl (H3K9me2) levels. Analyses in JMJD1C knockout mice also establish a JMJD1C requirement for RUNX1-RUNX1T1's ability to increase proliferation. We also show a critical role for JMJD1C in the survival of multiple human AML cell lines, suggesting that it is required for leukemic programs in different AML cell types through its association with key transcription factors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Blood Research Institute, Blood Center of Wisconsin, Milwaukee, Wisconsin 53226, USA.
ISSN:0890-9369
1549-5477
DOI:10.1101/gad.267278.115